Performance in Delivering Clinical Trials - Q3 2017/18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date agreed to recruit total number of participants	Total Number Of Study Participants Recruited at the agreed date	Total Number Of Study Participants Recruited	Date that the trial closed to recruitment	Reason For Closure Of Trial	Comments
16/NW/0787	216022	A phase IIa, randomized, double- blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (class III) mutation GLPG2222-CL-202	Number Agreed	1	1	Date Agreed	30/06/2017	0	0	30/06/2017	Recruitment Finished	Worldwide competitive recruitment over a short time period - recruitment finished before consent could take place on site
16/SC/0336	208403	Utilizing Novel dipole density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)	Number Agreed	25	25	Date Agreed	14/04/2017	16	16	14/04/2017	Recruitment Finished	
15/SC/0311	181166	VEST III PMS clinical protocol	Number Agreed	15	15	Date Agreed	21/07/2017	17	17	21/07/2017	Recruitment Finished	
15/EE/0368	186410	ABSORB bioresorbable scaffold vs. Xience metallic stent for prevention of restenosis following percutaneous coronary intervention in patients at high risk of restenosis	Number Agreed	50	50	Date Agreed	31/01/2018	89	89	21/09/2017	Withdrawn By Sponsor	
15/SC/0599	187727	A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection	Number Agreed	2	2	Date Agreed	31/07/2017	1	1	15/02/2017	Recruitment Finished	Study was competitive recruitment. Recruitment finished early due to a much higher rate of flu in Australia allowing more recruitment to take place there. Early closure did not allow us to reach our recruitment target. The project also had a high screening failure rate, with a screening to recruitment rate of less than 5%
16/LO/0793	203066	A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in pa	Number Agreed	3	3	Date Agreed	01/03/2017	10	10	01/04/2017	Recruitment Finished	
17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	43159	1	1	17/11/2017	Recruitment Finished	
17/EE/0090	222836	A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation.	Number Agreed	1	1	Date Agreed	43009	1	1	12/12/2017	Recruitment Finished	